TriSalus Life Sciences (TLSI) Stock Overview
Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TLSI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
TriSalus Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.10 |
| 52 Week High | US$5.88 |
| 52 Week Low | US$3.42 |
| Beta | 0.48 |
| 1 Month Change | 17.51% |
| 3 Month Change | 2.00% |
| 1 Year Change | -2.67% |
| 3 Year Change | -48.59% |
| 5 Year Change | n/a |
| Change since IPO | -51.52% |
Recent News & Updates
Shareholder Returns
| TLSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.8% | -1.1% | 1.9% |
| 1Y | -2.7% | -8.9% | 17.5% |
Return vs Industry: TLSI exceeded the US Biotechs industry which returned -8.9% over the past year.
Return vs Market: TLSI underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| TLSI volatility | |
|---|---|
| TLSI Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLSI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TLSI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 110 | Mary Szela | trisaluslifesci.com |
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer.
TriSalus Life Sciences, Inc. Fundamentals Summary
| TLSI fundamental statistics | |
|---|---|
| Market cap | US$254.32m |
| Earnings (TTM) | -US$34.18m |
| Revenue (TTM) | US$35.99m |
Is TLSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLSI income statement (TTM) | |
|---|---|
| Revenue | US$35.99m |
| Cost of Revenue | US$5.52m |
| Gross Profit | US$30.47m |
| Other Expenses | US$64.66m |
| Earnings | -US$34.18m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 84.67% |
| Net Profit Margin | -94.98% |
| Debt/Equity Ratio | -166.2% |
How did TLSI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/28 18:00 |
| End of Day Share Price | 2025/08/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TriSalus Life Sciences, Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Justin Walsh | JonesTrading Institutional Services, LLC |